Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) is a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium announced today the appointment of Steve O’Loughlin to the position of Senior Director of Finance and Corporate Development. In his new role, Steve will be a member of the leadership team and will report to Sandesh Seth, Executive Chairman of Actinium. Steve will be responsible for developing and executing the Company’s investor relations and corporate communications programs, interacting with the investment community as well as providing high-level financial support for Actinium’s strategic growth initiatives.
“Actinium is pleased to welcome Steve to team,” said Sandesh Seth, Executive Chairman of Actinium. “As we continue to progress our Iomab-B and Actimab-A programs in the clinic we look forward to having Steve on board to communicate our value proposition and developments to the investment community.”
“I am very excited to join the Actinium team and eager to assume my responsibilities,” said Mr. O’Loughlin. “Actinium continues to progress Iomab-B and Actimab-A through the clinic in indications with significant unmet medical needs while expanding its pipeline and I look forward to communicating and interacting with the investment community on our developments. With Iomab-B poised to enter a pivotal Phase 3 trial, Actimab-A moving towards a Phase 2 trial and an ever strengthening team it is an honor to join Actinium at such a momentous time for the Company.”
Steve joins Actinium with almost a decade of life sciences industry experience gained from previous positions in investment banking and publicly traded life sciences companies. Most recently, Steve held the position of Vice President, Corporate Finance and Development and was a corporate officer at Protea Biosciences, Inc., a publicly traded life sciences tools company. At Protea, Steve worked with the executive management team to raise capital, execute strategic partnerships such as the Company’s collaboration and co-marketing agreement with InSphero AG and represented the Company to the investment community. Previously, Steve held corporate development positions with Caliber I.D., a publicly traded diagnostics company, where he helped commercialize Caliber I.D.’s FDA cleared VivaScope®diagnostic device, supported academic research collaborations and supported the executive management team in the execution of private placements and the Company’s IPO. Steve previously worked in investment banking at Jesup & Lamont where he focused on the biotechnology and life sciences industries. Steve has a B.S. in Business Administration with a concentration in finance from Ramapo College of New Jersey and is pursuing his CFA designation. (Original Source)
Shares of Actinium Pharmaceuticals closed yesterday at $2.30. ATNM has a 1-year high of $8.12 and a 1-year low of $1.52. The stock’s 50-day moving average is $2.15 and its 200-day moving average is $2.51.
Actinium Pharmaceuticals Inc is a biopharmaceutical company which develops drugs for treatment of cancer. It is a development stage company.